Mice genetically inactivated in interleukin-17a receptor are defective in long-term control of mycobacterium tuberculosis infection

Immunology

Volumn 140, Issue 2, 2013, Pages 220-231

  Freches, Danielle ^a   Korf, Hannelie ^a,c   Denis, Olivier ^a   Havaux, Xavier ^b   Huygen, Kris ^a   Romano, Marta ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Interleukin 17A; Interleukin 17RA ; Tuberculosis

Indexed keywords

BACTERIAL ENZYME; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL LOAD; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME REACTIVATION; GENE INACTIVATION; IN VITRO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUBERCULOSIS; WILD TYPE;

INTERLEUKIN-17A; INTERLEUKIN-17RA-/-; TUBERCULOSIS;

ANIMALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, INTERLEUKIN-17; TUBERCULOSIS;

EID: 84883784746     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12130     Document Type: Article

References (52)

1. WHO. Global Tuberculosis Control 2011. Geneva: WHO, 2011.
2. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96:29-35.
3. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154-8.
4. Kaufmann SHE. How can immunology contribute to the control of tuberculosis ? Nat Rev Immunol 2001; 1:20-30.
5. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008; 43:402-7.
6. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011; 32:232-9.
7. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 2009; 11:365-70.
8. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226:57-79.
9. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556-67.
10. Happel KI, Lockhart EA, Mason CM, Porretta E, Keoshkerian E, Odden AR, Nelson S, Ramsay AJ. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect Immun 2005; 73:5782-8.
11. Okamoto Yoshida Y, Umemura M, Yahagi A et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010;184:4414-22.
12. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, Ghilardi N, deSauvage F, Cooper AM. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J Immunol 2005; 175:788-95.
13. Khader SA, Guglani L, Rangel-Moreno J et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 2011; 187:5402-7.
14. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8:369-77.
15. Freches D, Romano M, Korf H, Renauld JC, Van Snick J, Uyttenhove C, Huygen K. Increased pulmonary tumor necrosis factor α, interleukin-6 (IL-6), and IL-17A responses compensate for decreased γ interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice. Clin Vaccine Immunol 2011; 18:95-104.
16. Romano M, D'Souza S, Adnet PY, Laali R, Jurion F, Palfliet K, Huygen K. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from M. tuberculosis increases the survival time of M. bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006; 24:3353-64.
17. Cruz A, Fraga AG, Fountain JJ et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207:1609-16.
18. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519-28.
19. Tanghe A, D'Souza S, Rosseels V, Denis O, Ottenhoff THM, Dalemans W, Wheeler C, Huygen K. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001; 69:3041-7.
20. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown I, Young DB. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 1999; 67:4586-93.
21. Romano M, Denis O, D'Souza S, Wang XM, Ottenhoff THM, Brulet JM, Huygen K. Induction of in vivo functional Db restricted cytolytic T cell activity against a putative phosphate transport receptor of M. tuberculosis. J Immunol 2004; 172:6913-21.
22. Korf JE, Pynaert G, Tournoy K et al. Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma. Am J Respir Crit Care Med 2006; 174:152-60.
23. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 1998; 93:270-4.
24. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011; 23:1069-75.
25. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010; 21:413-23.
26. Passos ST, Silver JS, O'Hara AC, Sehy D, Stumhofer JS, Hunter CA. IL-6 promote NK cell production of IL-17 during toxoplasmosis. J Immunol 2010; 184:1776-83.
27. Smith E, Stark MA, Zarbock A, Burcin TL, Bruce AC, Vaswani D, Foley P, Ley K. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through "short-loop" inhibition via IL-17 receptor. J Immunol 2008; 181:1357-64.
28. Cooper AM, Mayer-Barber KD, Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol 2011; 4:252-60.
29. Aujla SJ, Chan YR, Zheng M et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14:275-81.
30. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann S. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997; 65:4843-9.
31. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induces early γ interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis. Infect Immun 2000; 68:3322-6.
32. Pedrosa J, Saunders BM, Appelberg R, Orme IM, Silva MT, Cooper AM. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun 2000; 68:577-83.
33. Seiler P, Aichele P, Bandermann S et al. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol 2003; 33:2676-86.
34. Martino A, Badell E, Abadie V et al. Mycobacterium bovis bacillus Calmette-Guérin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R -dependent nitric oxide production. J Immunol 2010; 184:2038-47.
35. + T cells during Mycobacterium tuberculosis infection. J Immunol 2011; 186:7110-9.
36. Blomgran R, Desvignes L, Briken V, Ernst JD. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 2012; 11:81-90.
37. Martineau AR, Newton SM, Wilkinson KA et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117:1988-94.
38. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
39. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
40. Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 2008; 226:191-204.
41. Majlessi L, Simsova M, Jarvis Z et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Imm 2006; 74:2128-37.
42. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-γ-inducible LRG-47. Science 2003; 302:654-9.
43. Bean AGD, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162:3504-11.
44. Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561-72.
45. Jacobs M, Togbe DE, Fremond C et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 2007; 9:623-8.
46. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129:311-21.
47. Iyoda M, Shibata T, Kawaguchi M, Hizama N, Yamaoka T, Kokubu F, Akizawa T. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF α and IL-1β. Am J Physiol Renal Physiol 2010; 298:779-87.
48. Redford PS, Boonstra A, Read S, Pitt J, Graham C, Stavropoulos E, Bancroft GJ, O'Garra A. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 2010; 40:2200-10.
49. Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009; 31:761-71.
50. Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Lee EJ, Orme IM, Gonzalez-Juarrero M. Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2009; 89:149-57.
51. Higgins SC, Jarnicki AG, Lavelle EC, Mills KHG. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006; 177:7980-9.
52. Lin Y, Ritchea S, Logar A et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009; 31:799-810.